Hormonal
Combined estrogen plus progestin therapy significantly reduces the risk of hip fractures and colorectal cancer in postmenopausal women.
While estrogen plus progestin therapy does reduce the risk of hip fractures and colorectal cancer, these benefits are not sufficient to justify the use of the therapy for primary prevention of chronic diseases due to the increased risks of heart disease, stroke, blood clots, and breast cancer.
Hip fracture, 0.66 (0.45-0.98)... Colorectal cancer, 0.63 (0.43-0.92)... absolute risk reductions per 10000 person-years were 6 fewer colorectal cancers and 5 fewer hip fractures.
Why this rating
Large-scale RCT with statistically significant results for these specific endpoints.
Source
Risks and Benefits of Estrogen Plus Progestin in Healthy Postmenopausal Women: Principal Results From the Women's Health Initiative Randomized Controlled Trial
Writing Group for the Women's Health Initiative Investigators · JAMA · 2002
DOI 10.1001/jama.288.3.321
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →